2022年12月最新中科院JCR期刊分区表数据(升级版)已经更新,欢迎查询! 如果您对期刊系统有任何需求或者问题,欢迎
反馈给我们。 ![]() |
基本信息 | 登录收藏 | |||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
期刊名字![]() | CANCER LETTERS CANCER LETT LetPub评分 9.0
55人评分
我要评分
声誉 10.0 影响力 8.2 速度 9.4 | |||||||||||||||||||||
期刊ISSN | 0304-3835 | 微信扫码收藏此期刊 | ||||||||||||||||||||
E-ISSN | 1872-7980 | |||||||||||||||||||||
2021-2022最新影响因子 (数据来源于搜索引擎) | 注册或登录后,查看影响因子和历年趋势图 | |||||||||||||||||||||
2021-2022自引率 | 2.00%注册或登录后,查看自引率趋势图 | |||||||||||||||||||||
h-index | 161 | |||||||||||||||||||||
CiteScore |
| |||||||||||||||||||||
期刊简介 | CANCER LETTERS is a journal providing rapid publication of full-length articles in the broad area of cancer research. The journal places emphasis on the molecular and cell biology of cancer, oncogenes, carcinogenesis, radiation biology, molecular pathology, hormones and cancer, viral oncology, biology of cancer and metastasis, molecular cytogenetics, epidemiology; and experimental therapeutics. The primary criterion for publication is interest to a multidisciplinary audience. Papers should be technically sound and substantiated by sufficient experimental detail. Clinical papers will be accepted if they contribute to the understanding of the basic mechanisms underlying disease. | |||||||||||||||||||||
期刊官方网站 | http://www.elsevier.com/wps/find/journaldescription.cws_home/506050/description#description | |||||||||||||||||||||
期刊投稿网址 | https://www.editorialmanager.com/CANLET | |||||||||||||||||||||
期刊语言要求 | Language Please write your text in good English (American or British usage is accepted, but not a mixture of these). Authors who feel their English language manuscript may require editing to eliminate possible grammatical or spelling errors and to conform to correct scientific English may wish to use the English Language Editing service. 经LetPub语言功底雄厚的美籍native English speaker精心编辑的稿件,不仅能满足CANCER LETTERS的语言要求,还能让CANCER LETTERS编辑和审稿人得到更好的审稿体验,让稿件最大限度地被CANCER LETTERS编辑和审稿人充分理解和公正评估。LetPub的专业SCI论文编辑服务(包括SCI论文英语润色,同行资深专家修改润色,SCI论文专业翻译,SCI论文格式排版,专业学术制图等)帮助作者准备稿件,已助力全球15万+作者顺利发表论文。部分发表范例可查看:服务好评 论文致谢 。 提交文稿 | |||||||||||||||||||||
是否OA开放访问 | No | |||||||||||||||||||||
通讯方式 | ELSEVIER IRELAND LTD, ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, IRELAND, 00000 | |||||||||||||||||||||
出版商 | Elsevier Ireland Ltd | |||||||||||||||||||||
涉及的研究方向 | 医学-肿瘤学 | |||||||||||||||||||||
出版国家或地区 | NETHERLANDS | |||||||||||||||||||||
出版语言 | English | |||||||||||||||||||||
出版周期 | Biweekly | |||||||||||||||||||||
出版年份 | 1975 | |||||||||||||||||||||
年文章数 | 511注册或登录后,查看年文章数趋势图 | |||||||||||||||||||||
Gold OA文章占比 | 15.33% | |||||||||||||||||||||
研究类文章占比: 文章 ÷(文章 + 综述) | 95.30% | |||||||||||||||||||||
WOS期刊SCI分区 ( 2021-2022年最新版) | WOS分区等级:1区
| |||||||||||||||||||||
中科院《国际期刊预警 名单(试行)》名单 | 2023年01月发布的2023版:不在预警名单中 2021年12月发布的2021版:不在预警名单中 2021年01月发布的2020版:不在预警名单中 | |||||||||||||||||||||
中科院SCI期刊分区 ( 2022年12月最新升级版) | 注册或登录后,查看中科院SCI期刊分区趋势图
| |||||||||||||||||||||
中科院SCI期刊分区 ( 2021年12月基础版) |
| |||||||||||||||||||||
中科院SCI期刊分区 ( 2021年12月升级版) |
| |||||||||||||||||||||
中科院SCI期刊分区 ( 2020年12月旧的升级版) |
| |||||||||||||||||||||
SCI期刊收录coverage | Science Citation Index Expanded (SCIE) (2020年1月,原SCI撤销合并入SCIE,统称SCIE) Scopus (CiteScore) | |||||||||||||||||||||
PubMed Central (PMC)链接 | http://www.ncbi.nlm.nih.gov/nlmcatalog?term=0304-3835%5BISSN%5D | |||||||||||||||||||||
平均审稿速度 | 网友分享经验: 平均2.7个月 来源Elsevier官网: 平均3.3周 | |||||||||||||||||||||
平均录用比例 | 网友分享经验: 约52.27% | |||||||||||||||||||||
LetPub助力发表 | 经LetPub编辑的稿件平均录用比例是未经润色的稿件的1.5倍,平均审稿时间缩短40%。众多作者在使用LetPub的专业SCI论文编辑服务(包括SCI论文英语润色,同行资深专家修改润色,SCI论文专业翻译,SCI论文格式排版,专业学术制图等)后论文在CANCER LETTERS顺利发表。
快看看作者怎么说吧:服务好评 论文致谢 | |||||||||||||||||||||
在线出版周期 | 来源Elsevier官网: 平均8.3周 | |||||||||||||||||||||
期刊常用信息链接 |
|
|
|
|
注册或登录后,查看自引率趋势图 |
注册或登录后,查看中科院SCI期刊分区趋势图 |
注册或登录后,查看年文章数趋势图 |
中国学者近期发表的论文 | |
1. | Loss of PDZK1 expression activates PI3K/AKT signaling via PTEN phosphorylation in gastric cancer Author: Chunjuan Zhao, Tao Tao, Longyan Yang, Qiong Qin, Ying Wang, Hua Liu, Ran Song, Xiaomei Yang, Qiqi Wang, Siyu Gu, Ying Xiong, Dong Zhao, Songlin Wang, Duiping Feng, Wen G. Jiang, Jun Zhang, Junqi He Journal: CANCER LETTERS, 2019, Vol., , DOI:10.1016/j.canlet.2019.03.043 DOI |
2. | Corrigendum to “GFRα2 prompts cell growth and chemoresistance through down-regulating tumor suppressor gene PTEN via Mir-17-5p in pancreatic cancer” [Cancer Lett. 380 (2) (2016 Oct 1) 434–41] Author: Jiangning Gu, Di Wang, Jiaqiang Zhang, Yi Zhu, Ying Li, Hao Chen, Minmin Shi, Xuelong Wang, Baiyong Shen, Xiaxing Deng, Qian Zhan, Gang Wei, Chenghong Peng Journal: CANCER LETTERS, 2019, Vol., , DOI:10.1016/j.canlet.2019.03.031 DOI |
3. | Corrigendum to ‘High-affinity human programmed death-1 ligand-1 variant promotes redirected T cells to kill tumor cells’ [Cancer Lett. 447 (2019) 164–173] Author: Zhaoduan Liang, Yanyan Li, Ye Tian, Huanling Zhang, Wenxuan Cai, Anan Chen, Lin Chen, Yifeng Bao, Bo Xiang, Heping Kan, Yi Li Journal: CANCER LETTERS, 2019, Vol., , DOI:10.1016/j.canlet.2019.03.026 DOI |
4. | DMBX1 promotes tumor proliferation and regulates cell cycle progression via repressing OTX2-mediated transcription of p21 in lung adenocarcinoma cell Author: Jing Luo, Kaichao Liu, Yu Yao, Qi Sun, Xiufen Zheng, Biqing Zhu, Quanli Zhang, Lin Xu, Yi Shen, Binhui Ren Journal: CANCER LETTERS, 2019, Vol., , DOI:10.1016/j.canlet.2019.03.045 DOI |
5. | Activation of PSGR with β-ionone suppresses prostate cancer progression by blocking androgen receptor nuclear translocation Author: Hongjun Xie, Tianjie Liu, Jiaqi Chen, Zhao Yang, Shan Xu, Yizeng Fan, Jin Zeng, Yule Chen, Zhenkun Ma, Yang Gao, Dalin He, Lei Li Journal: CANCER LETTERS, 2019, Vol., , DOI:10.1016/j.canlet.2019.03.044 DOI |
6. | Macrophage-derived CCL22 promotes an immunosuppressive tumor microenvironment via IL-8 in malignant pleural effusion Author: Dong Wang, Li Yang, Dongli Yue, Ling Cao, Lifeng Li, Dan Wang, Yu Ping, Zhibo Shen, Yujia Zheng, Liping Wang, Yi Zhang Journal: CANCER LETTERS, 2019, Vol., , DOI:10.1016/j.canlet.2019.03.040 DOI |
7. | The μ-opioid receptor (MOR) promotes tumor initiation in hepatocellular carcinoma Author: Yi Li, Gang Li, Tao Tao, Xing Kang, Chang Liu, Xu Zhang, Chunyi Wang, Chong Li, Xiangyang Guo Journal: CANCER LETTERS, 2019, Vol., , DOI:10.1016/j.canlet.2019.03.038 DOI |
8. | Preclinical comparison of regorafenib and sorafenib efficacy for hepatocellular carcinoma using multimodality molecular imaging Author: Shengnan Liu, Yang Du, He Ma, Qian Liang, Xu Zhu, Jie Tian Journal: CANCER LETTERS, 2019, Vol., , DOI:10.1016/j.canlet.2019.03.037 DOI |
9. | HIF-1α mediates tumor-nerve interactions through the up-regulation of GM-CSF in pancreatic ductal adenocarcinoma Author: Haotian Wang, Rujiang Jia, Tiansuo Zhao, Xin Li, Mingxiao Lang, Chungen Lan, Hongwei Wang, Zengxun Li, Bodong Zhou, Liangliang Wu, Yan Sun, Xiuchao Wang, He Ren, Jihui Hao Journal: CANCER LETTERS, 2019, Vol., , DOI:10.1016/j.canlet.2019.03.036 DOI |
10. | Induction of breast cancer stem cells by M1 macrophages through Lin-28B-let-7-HMGA2 axis Author: Liang Guo, Xiang Cheng, Hongyu Chen, Changguo Chen, Shuai Xie, Min Zhao, Dan Liu, Que Deng, Yanjun Liu, Xiaomeng Wang, Xintian Chen, Jiangong Wang, Zhaoyang Yin, Siyong Qi, Jiangping Gao, Yuanfang Ma, Ning Guo, Ming Shi Journal: CANCER LETTERS, 2019, Vol., , DOI:10.1016/j.canlet.2019.03.032 DOI |
|
|
以上SCI期刊相关数据和信息来源于网络,仅供参考。
投稿状态统计: 我要评分: | |
同领域作者分享投稿经验:共17条 (包含回复) |
我来分享 |
|
联系我们 | 站点地图 | 友情链接 | 授权代理商 | 加入我们
© 2010-2023 中国: LetPub上海分公司 网站备案号:沪ICP备10217908号-1 沪公网安备号:31010402006960
增值电信业务经营许可证:沪B2-20211595
礼翰商务信息咨询(上海)有限公司 办公地址:上海市徐汇区漕溪北路88号圣爱大厦2103室
United States: Tel: 1-781-202-9968 Address: 400 5th Ave, Suite 530, Waltham, Massachusetts 02451